INSMED INCORPORATED

INSM · NASDAQ

Pharmaceutical Preparation Manufacturing · US

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United Statesand the European Union to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a growing footprint across Europeand in Japan. .

Market Data

Price $143.85 +0.72 (+0.50%)

Market Cap$31.01B

P/E Ratio—

EPS$—

52W High$212.75

52W Low$60.40

Beta1.23

Data from Finnhub · Updated Mar 11, 2026